Motion monitoring during a course of lung radiotherapy with anchored electromagnetic transponders

Quantification of inter- and intrafraction motion and variability of relative transponder positions

Daniela Schmitt1,2,3 · Simeon Nill1,2,4 · Falk Roeder5,6 · Daniela Gompelmann7,8 · Felix Hert7,8 · Uwe Oelfke1,2,4

Received: 2 February 2017 / Accepted: 30 June 2017 / Published online: 21 July 2017
© The Author(s) 2017. This article is an open access publication.

Abstract
Purpose Anchored electromagnetic transponders for tumor motion monitoring during lung radiotherapy were clinically evaluated. First, intrafractional motion patterns were analyzed as well as their interfractional variations. Second, intra- and interfractional changes of the geometric transponder positions were investigated.

Materials and methods Intrafractional motion data from 7 patients with an upper or middle lobe tumor and three implanted transponders each was used to calculate breathing amplitudes, overall motion amount and motion midlines in three mutual perpendicular directions and three-dimensionally (3D) for 162 fractions. For 6 patients intra- and interfractional variations in transponder distances and in the size of the triangle defined by the transponder locations over the treatment course were determined.

Results Mean 3D values of all fractions were up to 4.0, 4.6 and 3.4 mm per patient for amplitude, overall motion amount and midline deviation, respectively. Intrafractional transponder distances varied with standard deviations up to 3.2 mm, while a maximal triangle shrinkage of 36.5% over 39 days was observed.

Conclusions Electromagnetic real-time motion monitoring was feasible for all patients. Detected respiratory motion was on average modest in this small cohort without lower lobe tumors, but changes in motion midline were of the same size as the amplitudes and greater midline motion can be observed in some fractions. Intra- and interfractional variations of the geometric transponder positions can be large, so for reliable motion management correlation between transponder and tumor motion needs to be evaluated per patient.

Keywords Intrafraction motion · Lung radiotherapy · Electromagnetic tracking · Stability of marker positions · Motion management
Bewegungsdetektion während der Strahlentherapie der Lunge mit verankerten elektromagnetischen Transpondern

Quantifizierung von inter- und intrafraktioneller Bewegung und Variabilität der relativen Transponderpositionen

Zusammenfassung

Ziel Verankerte, elektromagnetische Transponder für die Bewegungserkennung des Tumors während der Strahlentherapie der Lunge wurden klinisch evaluiert. Dafür wurden intrafraktionale Bewegungsmuster und ihre interfraktionalen Variationen analysiert und intra- und interfractionelle Veränderungen der geometrischen Transponderpositionen untersucht.

Material und Methoden Intrafraktionale Bewegungsdaten von 7 Patienten mit einem Ober- oder Mittellappentumor und je drei implantierten Transpondern wurden benutzt, um Atemamplituden, Gesamtbewegungsaufkommen und Bewegungsmittellinien für die drei zueinander senkrechtten Bewegungsrichtungen und dreidimensional (3D) in 162 Fraktionen zu berechnen. Für 6 Patienten wurden intra- und interfractionelle Variationen der Transponderabstände und der Größe des von den Transponderpositionen definierter Dreiecks im Therapieverlauf bestimmt.

Ergebnisse Die mittleren 3D-Werte aller Fraktionen pro Patient ergaben bis zu 4,0, 4,6 und 3,4 mm für Amplitude, Gesamtbewegungsaufkommen und Mittellinienveränderung. Intrafraktionale Transponderabstände variierten mit Standardabweichungen von bis zu 3,2 mm, während eine maximale Verkleinerung der Dreiecksgröße um 36,5 % über 39 Tage beobachtet wurde.

Schlussfolgerung Elektromagnetische Echtzeit-Bewegungserkennung war für alle Patienten durchführbar. In dieser kleinen Patientenkohorte ohne Unterlappentumor war die detektierte Atembewegung im Mittel moderat. Jedoch waren Veränderungen der Bewegungsmittellinie in der gleichen Größe wie die Atemamplituden; in einzelnen Fraktionen konnten größere Mittellinienbewegungen beobachtet werden. Intra- und interfractionelle Variationen der geometrischen Transponderpositionen können erheblich sein, so dass für ein zuverlässiges Bewegungsmangement die Korrelation zwischen Transponder- und Tumorbewegung für jeden Patienten untersucht werden sollte.

Schlüsselwörter Intrafraktionale Bewegung · Strahlentherapie der Lunge · Elektromagnetisches Tracking · Stabilität von Markerpositionen · Bewegungsmanagement

Radiotherapy is a cornerstone of curative intent treatment for early and advanced lung cancer, see e.g. [1–6]. Thereby intrafractional tumor motion is a main challenge because it potentially causes deviations between the planned and delivered doses in high precision therapy [7]. A new method for three-dimensional (3D) real-time lung tumor motion monitoring without imaging dose is the continuous detection of implanted anchored electromagnetic transponders [8] available for the Calypso® system (Varian Medical Systems, Inc., Palo Alto, CA, USA). These transponders have a capsule with expandable nitinol legs for fixation in small airways and are implanted in lung tissue bronchoscopically under continuous fluoroscopic guidance within 3 cm distance to the lesion. Recently, a report of the first patient treated with multileaf collimator (MLC) tracking based on them was published [9]. Here we report the evaluation of collected motion data from patients studied at our center who have been enrolled in a multicenter trial investigating safety and stability of the anchored transponders in a wider patient collective. Each patient had three transponders implanted and the Calypso® system reported single transponder as well as transponder-centroid translations in lateral, longitudinal and vertical direction. Each transponder was updated with a rate of approximately 3.3 Hz, leading to a continuously updated centroid position of approximately 10 Hz, always using the latest position information of each transponder. With this data we were able to quantify the intrafractional motion during lung treatments and their interfractional variations. Additionally, we evaluated the stability of intrafractional motion within fractions because all systems which aim to adapt treatment directly after motion detection (e.g. MLC tracking [10–12]) need motion prediction due to system latency, see e.g. [13, 14]. The quality of these predictions depend on intrafractional regularity of the motion patterns. To study this regularity, motion patterns of the two patients with the largest 3D amplitudes were further analyzed via quantification of changes between adjacent beam-on and beam-off phases. Since the transponder-centroid position is only a surrogate for motion of the lung lesion, we quantified the intra- and interfractional changes of individual transponder positions via calculation of intertransponder distance variation.

Materials and methods

Patient data

Seven lung cancer patients suffering from an upper or middle lobe tumor were enrolled at the German Cancer Research Center within the aforementioned multicenter trial (ClinicalTrials.gov NCT01396551) organized by Varian Medical Systems, Inc. The trial was approved by the ethics committee of the medical faculty at Heidelberg university. Intrafractional motion data of the bronchoscopically implanted electromagnetic transponders was used for all presented investigations. Two patients received
hypofractionated 3D conformal radiotherapy (3D CRT) in 10 fractions and 5 patients were treated with step-and-shoot IMRT in 28–31 fractions. Tumor positions and number of evaluated fractions for our study are listed in Table 1. For the evaluations of single transponder motions one IMRT patient (P5) was excluded because one transponder had exceeded the allowed distance of 7.5 cm specified by the manufacturer [15]. Average delivery time of a treatment fraction was 4.5 min (9.6 min) for 3D CRT (IMRT) patients. For all investigations single transponder and transponder-centroid positions were linearly interpolated to the same 10 Hz grid to obtain synchronized information for all transponders and to equalize the original fluctuations in update rate.

### Table 1  Results of transponder-centroid motion evaluation for all patients

| Patient | Tumor position | Evaluated fractions | Mean of fraction midline (mean ± SD) [mm] | SD of fraction midline (mean ± SD) [mm] | Mean of overall fraction motion (mean ± SD) [mm] | Amplitude around current midline (mean ± SD) [mm] |
|---------|----------------|---------------------|------------------------------------------|----------------------------------------|-----------------------------------------------|-------------------------------------------------|
|         | RUL            | 10                  | 0.0 ± 0.3                                 | 0.4 ± 0.7                              | 3.4 ± 0.8                                     | 0.8 ± 0.3                                      |
|         | LUL            | 10                  | 0.0 ± 0.3                                 | 0.4 ± 0.7                              | 3.4 ± 0.8                                     | 0.8 ± 0.3                                      |
|         | LUL            | 31                  | 0.1 ± 0.4                                 | 0.1 ± 0.4                              | 1.8 ± 0.5                                     | 0.3 ± 0.1                                      |
|         | RML            | 26                  | 0.4 ± 0.7                                 | 0.4 ± 0.7                              | 3.4 ± 0.8                                     | 0.8 ± 0.3                                      |
|         | LUL            | 29                  | 0.7 ± 0.8                                 | 0.2 ± 0.5                              | 1.8 ± 0.5                                     | 0.3 ± 0.1                                      |
|         | RML            | 29                  | 0.1 ± 0.4                                 | 0.0 ± 0.4                              | 1.8 ± 0.5                                     | 0.3 ± 0.1                                      |
|         | RML            | 27                  | 0.6 ± 0.4                                 | 0.6 ± 0.3                              | 3.4 ± 0.8                                     | 0.8 ± 0.3                                      |

**Referring to the supplementary material:**

- **M**$_{\text{mean}}$ ± **M**$_{\text{SD}}$
- **M**$_{\text{SD}}$ ± **M**$_{\text{SD}}$

**Results of transponder-centroid motion evaluation for all patients**

The midline position for the time the irradiation started $t_i$ was called initial midline: $M_{\text{initial}}^f = M_{\text{initial}}^f$. The midline variations per fraction were calculated as mean $M_{\text{initial}}^f$ and standard deviation (SD) $M_{\text{SD}}^f$ of the midline positions relative to $M_{\text{initial}}^f$. From these fraction values means and SDs were calculated per patient to quantify the interfractional variations of the mean midline deviation ($M_{\text{mean}}^f$ and $M_{\text{SD}}^f$) and the interfractional variations of the intrafractional width of midline positions ($M_{\text{SD}}^f$ and $M_{\text{SD}}^f$).

For quantification of overall motion amount all centroid positions $r_i^f$ were analyzed in relation to the corresponding $M_{\text{initial}}^f$ for all three directions separately and in 3D. For each fraction, means and SDs were calculated and from these values interfractional means and SDs per patient as above.

For each in- and exhale peak the distance between $r_i^f$ and the midline defined for the same point in time $M_{\text{initial}}^f$ was calculated to determine motion amplitudes in lateral, longitudinal and vertical direction and in 3D relative to the actual midline. Data from all peaks were averaged to...
Fig. 1 Example of longitudinal transponder-centroid motion for fraction 4 of patient 1. The longitudinal midline and the beam-on times are also indicated. The initial midline is set to zero. The intervals $I_1, I_2$ and $I_3$ related to the 4th beam-off phase are shown as example.

Rive a mean fraction amplitude. From these amplitudes the mean amplitude per patient was calculated with the corresponding SD.

For investigation of intrafractional changes between adjacent beam-on and beam-off phases motion patterns of the two patients with the largest 3D amplitudes were further analyzed. For each beam-off time (lasting about 20 s), three intervals of the same length $I_1, I_2$ and $I_3$ were defined, where $I_2$ refers to the beam-off interval and $I_1$ and $I_3$ denote the adjacent beam phases before and after the beam-off time. For these intervals the SD of centroid positions, as surrogate for overall motion amount and the mean motion midline, were determined for three mutually perpendicular directions and in 3D. The differences between these adjacent intervals were evaluated.

An example of detected motion with plotted midline and indicated times of irradiation can be found in Fig. 1.

Intertransponder variations

Variations in transponder positions were evaluated regarding intra- and interfractional distance changes. First, transponder distances were calculated from the interpolated single transponder data for all points in time between start of first and end of last beam for all three directions. From these distances the fraction SDs were calculated.

To study the origin of intrafractional variations, linear correlations between the longitudinal SDs of transponder distances and three parameters potentially affecting relative transponder motion were evaluated. These parameters were (I) the fraction mean 3D distance of the transponder pair, (II) the mean 3D amplitude of the transponder-centroid in the corresponding fraction and (III) the product of (I) and (II).

In addition, the interfractional changes in the individual transponder positions were analyzed. Therefore 3D transponder distances were used for determination of the area of the triangle defined by the location of the transponders. For each fraction, the mean and SD of the triangle area were calculated to evaluate the overall trend. Linear regressions of the 3D distances with the day after first fraction were averaged to determine a mean distance change per day (6 patients × 3 transponder distances = 18 regressions). Furthermore, mean 3D transponder distances of the first fraction were defined as patient-specific initial distances and it was investigated which percentage of the 381 mean distances measured in the following fractions were within 1 and 2 mm.

Results

Transponder-centroid motion quantification

The overall motion amount for all patients can be seen in Fig. 2 as a boxplot of all transponder-centroid positions relative to the corresponding initial midline. Quantitative
results of the intra- and interfractional changes in motion midline and overall motion are presented in Table 1 with the breathing amplitudes. The unidirectional motion midline means of fraction means range from –1.5 to 0.7 mm with SDs between 0.3 and 1.6 mm representing the interfractional variations. The majority of these means of fraction means are very close to zero as anticipated for a periodic breathing motion. The corresponding calculations for the mean of overall motion resulted in the same values, which has to be expected, as the midline mean is calculated from nearly the same data (plus 5 s in the beginning and the end of each fraction) using one additional averaging. The three-dimensional means of fraction means, whose results are not dominated by the compensation of positive and negative position values, show values up to 3.4 mm for the motion midline and up to 4.6 mm for the overall motion. These values are not the same because of the additional calculation of vector norm, which does not commute with the averaging. The means and SDs of the fraction SDs in midline and overall motion amount describe the intrafractional variations and their change between fractions. Because of the averaging, means of SDs are generally larger for the overall motion than for the midline. Maximum unidirectional values are 3.0 and 1.9 mm, respectively. Maximum SD describing interfractional changes is 0.9 mm.

For two of the seven patients no amplitude was observed to be larger than 1 mm. The maximum unidirectional amplitudes of the other five patients are either in the longitudinal or the vertical direction, ranging from 1.6 to 3.2 mm. Three-dimensional amplitudes were observed to be between 0.5 and 4.0 mm, while the interfractional change of amplitudes was small with all SDs well below 1 mm.

The two patients with the largest 3D amplitude are P1 and P4. The evaluation of motion differences in adjacent beam-on and beam-off phases considers 3 intervals for each of the 5 beam-off times per fraction for P1 and 8 beam-off times per fraction for P4 (all IMRT segments with the same gantry angle are summarized to one beam including the short breaks between segments). P1 shows remarkable deviations between adjacent intervals, e.g. a mean difference of vertical midline of 1.4 mm and maximum values of 7.0 mm for longitudinal and 9.1 mm for vertical midline, while for P4 (second largest motion amount) all studied differences are negligible.

**Intertransponder variations**

Intrafractional longitudinal transponder distances vary with SDs up to 3.2 mm. All lateral and vertical SDs are below 1 mm, hence they were not studied further. Correlation analyses between longitudinal distance SDs with 3D transponder distances (Pearson’s correlation coefficient $r = 0.42$) and 3D transponder-centroid amplitudes ($r = 0.49$) show poor results, while their product is strongly correlated to the longitudinal SDs ($r = 0.83$, $p < 0.001$). This shows that only the coincidence of large transponder distances and overall motion amount leads to large interfractional transponder distance variations. Fig. 3 shows the plot of all longitudinal SDs of all patients against the corresponding product of mean 3D transponder distance and mean 3D transponder-centroid amplitude per fraction.

For all 6 patients the transponder triangle area shrunk over the treatment course, see Fig. 4. A maximum decrease of 36.5% was observed for P7. The triangle shrinkage resulted from heterogeneous interfractional transponder distance variations; 16 of 18 distances shrunk and 2 distances grew. The mean 3D transponder distance change per day after first fraction, determined via averaging of regressions, resulted in $-0.07 \text{ mm} \pm 0.08 \text{ mm}$. The largest slope in the linear regression, namely $-0.25 \text{ mm per day}$ was found in P7. Considering all mean 3D transponder distances per fraction, the difference to the first fraction is maximum 1 mm (2 mm) for 47% (73%) of distances.

**Discussion**

**Transponder-centroid motion quantification**

Published analyses of lung tumor motion found an increasing motion amount with decreasing distance to the diaphragm, e.g. [16]. Because the tumors in the current work are located in an upper or middle lobe, data from lower lobe tumors were removed from published data for comparison, if not stated different. In the current study, amplitude is defined as distance from midline to peak,
Fig. 4  Triangle area defined by the transponder positions per day of all 6 patients (means with standard deviations depicted by error bars). Each vertical axis covers a range of 2 cm²

while in the image-based data, used for comparison in the following, a peak-to-peak amplitude is used. Therefore, current results were doubled for comparison finding good agreement between image-based and electromagnetically detected motion. Considering 11 patients from an analysis using respiration correlated cone-beam CT (CBCT) [17], mean 3D amplitude extracted from 6 CTs per patient can be calculated to 3.7 mm ± 3.2 mm. The corresponding value for our data is 4.5 mm ± 2.5 mm. Mean unidirectional amplitudes determined from lung marker motion detected fluoroscopically with 30 Hz [16] result in 1.2 mm ± 0.9 mm, 3.2 mm ± 3.2 mm and 2.6 mm ± 2.2 mm for lateral, longitudinal and vertical motion, respectively, considering only the 13 patients with tumors in an upper or middle lobe. Our data results in 1.8 mm ± 1.0 mm, 2.9 mm ± 2.6 mm and 2.4 mm ± 1.9 mm.

Large intrafractional changes in motion midline were observed, especially in P1, where the mean of midline deviations from fraction specific initial midline over all fractions is 3.4 mm in 3D. The largest difference in unidirectional mean midline position between two consecutive intervals of approximately 20 s was found in the same patient to be 9.1 mm in vertical direction. Maximum longitudinal drift in mean tumor position determined from repeated 4D CT scans [18] was 6.9 mm for one lower lobe tumor within 30 min.

These results show the possibility of relevant variations in motion patterns during a course of treatment. This should be kept in mind during margin definition for conventional therapy without continuous motion detection based on one pretreatment 4D CT as well as for beam-tracking techniques relying on aforementioned motion prediction methods.

Intertransponder variations

The amount of intrafractional variation in transponder distances found here depends on the combination of intertransponder distance and overall motion amount. As the motion amount for each patient is unknown before therapy, the intertransponder distances should be as small as possible, regarding minimum distance of 1 cm requested by the system [9]. Concurrently, for good representation of tumor motion it is desirable to enclose the whole tumor with the transponders, while the transponder-centroid should be as close to the tumor-centroid as possible. Since there is no published data available for intrafractional distance variations of implanted lung markers, only interfractional variations in 3D distance found here can be compared with published data on bronchoscopically placed gold markers [19]. Reported intermarker distances measured with stereoscopic fluoroscopic x-ray imaging for 11 hypofractionated patients during 1 to 2 weeks of treatment differ maximum 1 mm (2 mm) from the initial distances (determined from planning CT) for 80% (95%) of 198 measurements in 71 setups. The fraction mean 3D transponder distances in this work differs much more from the first fraction with 47% (73%) for 1 mm (2 mm). But, considering only the first 14 days after start of treatment, our values increase to 71% (88%) and for the first 7 days, they grow to 81% (90%). Thus, the transponder or marker distance changes seem not to arise from differences in e. g. fixation, but from tissue reaction
on irradiation (like tumor shrinkage). The extent of these reactions is larger for longer observation times because of the time needed for tissue response.

Changes in intertransponder distances suggest geometry variations in the surrounding tissue, possibly modifying the tumor and organs at risk (OAR) geometry in general and especially the relationship of transponder-centroid and tumor-centroid from the planning CT. Intertransponder-marker-to-tumor-centroid displacements for bronchoscopically implanted gold coils, measured in weekly 4D CBCTs over 7 weeks in 7 patients [20], resulted e.g. in a mean 3D distance change of 5 mm ± 3 mm. A recent study on 71 conventional fractionated lung cancer patients without markers receiving at least a weekly kV CBCT shows a replanning necessity in 60% of the patients due to geometrical changes in tumor or OARs [21].

The Calypso® system measures transponder distances during the localization procedure of each fraction. This data can be used to establish geometrical changes within irradiated lung tissue and may be useful as a future surrogate indicating lung toxicity or therapy response.

Conclusions

Electromagnetic real-time motion monitoring of the transponder-centroid was feasible for all patients. Detected motion shows that tumor midline motion can be of the same size as the breathing amplitude. In addition, there can be large changes between adjacent time intervals. These results should be kept in mind when choosing treatment technique, proper margins and tracking method, if available. Image-based geometry monitoring should be performed on a regular basis to enable an adaption of treatment to changed geometry of transponders, tumor and OARs.

Funding

We thank the German Research Foundation DFG (SFB/TRR 125) for partly funding this project. In addition, we thank Varian Medical Systems, Inc. for organizing the multicenter trial and providing the transponders and support for transponder implantation and motion monitoring application.

Compliance with ethical guidelines

Conflict of interest

D. Schmitt, S. Nill, F. Roeder, D. Gompelmann, F. Hirth and U. Oelfke declare that they have no competing interests.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Padda SK, Burt BM, Trakul N, Wakelee HA (2014) Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol 41(1):40–56. doi:10.1053/j.seminoncol.2013.12.011
2. Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190. doi:10.1200/jco.2009.26.2543
3. Schanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191(2):125–132. doi:10.1007/s00066-014-0739-5
4. Zehtenmayr F, Wurstbauer K, Deutschmann H et al (2015) DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (IIb) non-small-cell lung cancer. Strahlenther Onkol 191(3):256–263. doi:10.1007/s00066-014-0754-6
5. Wurstbauer K, Zehtenmayr F, Deutschmann H et al (2017) DART-bid for loco-regionally advanced NSCLC: summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints. Strahlenther Onkol 193(4):315–323. doi:10.1007/s00066-016-1095-4
6. Simeonova-Chergou A, Jahnke A, Siebenlist K et al (2016) Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients. Strahlenther Onkol 192(3):166–173. doi:10.1007/s00066-015-0934-z
7. Korreman SS (2015) Image-guided radiotherapy and motion management in lung cancer. Br J Radiol 88(1051).20150100. doi:10.1259/bjr.20150100
8. Shah AP, Kupelian PA, Willoughby TW, Meeks SL (2011) Expanding the use of real-time electromagnetic tracking in radiation oncology. J Appl Clin Med Phys 12(4):34–49. doi:10.1120/jacmp.v12i4.3590
9. Booth JT, Caillot V, Hardcastle NE et al (2016) The first patient treatment of electromagnetic-guided real time adaptive radiotherapy using MLC tracking for lung SABR. Radiother Oncol 121(1):19–25. doi:10.1016/j.radonc.2016.08.025
10. Krauss A, Nill S, Tacke M, Oelfke U (2011) Electromagnetic real-time tumor position monitoring and dynamic multileaf collimator tracking using a siemens 160 MLC: geometric and dosimetric accuracy of an integrated system. Int J Radiat Oncol Biol Phys 79(2):579–587. doi:10.1016/j.ijrobp.2010.03.043
11. Fast MF, Nill S, Bedford JL, Oelfke U (2014) Dynamic tumor tracking using the Elekta Agility MLC. Med Phys 41(11):11719. doi:10.1118/1.4899175
12. Keall PJ, Colvill E, O’Brien R et al (2014) The first clinical implementation of electromagnetic transponder-guided MLC tracking. Med Phys 41(2):020702. doi:10.1118/1.4862509
13. Krauss A, Nill S, Oelfke U (2011) The comparative performance of four respiratory motion predictors for real-time tumour tracking. Phys Med Biol 56(16):5303–5317. doi:10.1088/0031-9155/56/16/015
14. Dürrchen R, Wissel T, Ernst F, Schlaefer A, Schweikard A (2014) Multivariate respiratory motion prediction. Phys Med Biol 59(20):6043–6060. doi:10.1088/0031-9155/59/20/6043
15. Varian Medical Systems (2014) Beacon care package-lung, Instructions for use, LBL0146-001. 10 Oct
16. Seppenwoolde Y, Shirato H, Kitamura K et al (2002) Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 53(4):822–834. doi:10.1016/s0360-3016(02)02803-1
17. Bissonnette J-P, Franks KN, Purdie TG et al (2009) Quantifying interfraction and intrafraction tumor motion in lung stereotactic body radiotherapy using respiration-correlated cone beam computed tomography. Int J Radiat Oncol Biol Phys 75(3):688–695. doi:10.1016/j.ijrobp.2008.11.066
18. Guckenberger M, Wilbert J, Meyer J, Baier K, Richter A, Flentje M (2007) Is a single respiratory correlated 4D-CT study sufficient for evaluation of breathing motion? Int J Radiat Oncol Biol Phys 67(5):1352–1359. doi:10.1016/j.ijrobp.2006.11.025
19. Imura M, Yamazaki K, Shirato H et al (2005) Insertion and fixation of fiducial markers for setup and tracking of lung tumors in radiotherapy. Int J Radiat Oncol Biol Phys 63(5):1442–1447. doi:10.1016/j.ijrobp.2005.04.024
20. Roman NO, Shepherd W, Mukhopadhyay N, Hugo GD, Weiss E (2012) Interfractional positional variability of fiducial markers and primary tumors in locally advanced non-small-cell lung cancer during audiovisual biofeedback radiotherapy. Int J Radiat Oncol Biol Phys 83(5):1566–1572. doi:10.1016/j.ijrobp.2011.10.051
21. Elsayad K, Kriz J, Reinartz G et al (2016) Cone-beam CT-guided radiotherapy in the management of lung cancer: diagnostic and therapeutic value. Strahlenther Onkol 192(2):83–91. doi:10.1007/s00066-015-0927-y